SCHEMBL15344161

SCHEMBL15344161

COc1cncc(-c2cc(C)ccn2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.57
CCR1 P32246 2/20 0.50
CCR5 P51681 2/20 0.50
CCR8 P51685 2/20 0.50
CYP11B1 P15538 7/20 0.47
CYP11B2 P19099 7/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP1A1 P04798 2/20 0.44
CYP1B1 Q16678 2/20 0.44
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
MKNK2 Q9HBH9 2/20 0.43
MKNK1 Q9BUB5 1/20 0.43
FYN P06241 2/20 0.43
ROS1 P08922 1/20 0.41
CYP2E1 P05181 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19569868 0.81 CYP2A6 (0.66) CYP2A6CCR1CCR5CCR8CYP11B1
SCHEMBL15340903 0.80 CYP11B1 (0.44) CYP2A6CCR1CCR5CCR8CYP11B1
SCHEMBL913245 0.80 CCR1 (0.57) CYP2A6CCR1CCR5CCR8ABL1
SCHEMBL14607593 0.79 GRM5 (0.54) CYP2A6CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL14850486 0.79 CYP3A4 (0.51) CYP2A6CCR1CCR5CCR8CYP11B1
SCHEMBL29248884 0.77 CYP2A6 (0.60) CYP2A6CCR1CCR5CCR8CYP11B1
SCHEMBL29248956 0.77 CYP2A6 (0.60) CYP2A6CCR1CCR5CCR8CYP11B1
SCHEMBL9014003 0.75 CCR1 (0.80) CYP2A6CCR1CCR5CCR8ABL1
SCHEMBL9014019 0.75 CCR1 (0.80) CYP2A6CCR1CCR5CCR8ABL1
SCHEMBL14554394 0.75 CCR1 (0.80) CYP2A6CCR1CCR5CCR8ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160152582-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-06-02 US disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-9096586-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-08-04 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281434-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-10-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281434-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 CYP2A6 2409/4885CCR1 886/4885CCR5 225/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP2A6 855/4885CCR1 106/4885CCR5 3/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP2A6 855/4885CCR1 106/4885CCR5 3/4885
US-20160152582-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 CYP2A6 2409/4885CCR1 886/4885CCR5 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.